Amylyx Pharma To Present Phase 3 Topline Data Highlighting Avexitide’s Efficacy And Safety At ObesityWeek 2026 Annual Meeting

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) will present topline results from its Phase 3 LUCIDITY clinical trial of avexitide at the ObesityWeek 2026 Annual Meeting, scheduled for November 14-17, 2026. Avexitide is a first-in-class GLP-1 receptor antagonist targeting post-bariatric hypoglycemia (PBH), a condition with no FDA-approved therapy. The company previously announced positive topline results from the trial in August 2026. Additionally, a second presentation will discuss a machine learning approach to identify individuals with PBH using real-world claims data.